TaiGen Announces FDA Approval of IND for Its Flu Antiviral TG-1000
The Pharma Data
OCTOBER 31, 2020
With the IND approval in place, we are ready and eager to extend the clinical study of TG-1000 to the U.S. billion USD by 2026 at a CAGR of 11.5%. Currently the market is comprised primarily of the neuraminidase inhibitor oseltamivir and the newly developed endonuclease inhibitor baloxavir. in the near future.”
Let's personalize your content